Fecal Microbiota Transplantation (FMT) in the Treatment of Pouchitis
Launched by HELSINKI UNIVERSITY CENTRAL HOSPITAL · Dec 14, 2017
Trial Information
Current as of June 25, 2025
Completed
Keywords
ClinConnect Summary
Pouchitis is the most common long term complication among patients with ulcerative colitis who have undergone restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). The etiology of pouchitis remains unclear. There is significant clinical evidence implicating bacteria in the pathogenesis. It has been shown that fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile -infection. Case reports have also shown promising results of FMT in patients with inflammatory bowel disease. Currently there is no established effective treatment for ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Status post of restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis
- • Pouchitis diagnosed by the symptoms and by endoscopy including histology within 6 months prior to FMT
- • Need of frequent or continuous use of antibiotics or probiotics because of the chronic pouchitis
- • Availability of consecutive fecal samples during one year
- • Compliance to attend FMT and control pouchoscopy after 52 weeks
- Exclusion Criteria:
- • Unable to provide informed consent
- • Use of immunosuppressive or biological medication
- • Use of corticosteroids
- • Acute pouchitis
- • Pregnancy
About Helsinki University Central Hospital
Helsinki University Central Hospital (HUCH) is a leading academic medical institution in Finland, dedicated to advancing healthcare through innovative research and clinical excellence. As a pivotal sponsor of clinical trials, HUCH integrates cutting-edge medical practices with rigorous scientific inquiry, fostering collaborations between researchers, healthcare professionals, and patients. The hospital is committed to enhancing patient outcomes and contributing to the global body of medical knowledge by conducting high-quality, ethically sound clinical studies across a diverse range of therapeutic areas. With a strong emphasis on education and training, HUCH plays a vital role in shaping the next generation of healthcare leaders and researchers.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, , Finland
Patients applied
Trial Officials
Anna Lepistö, PhD, MD
Study Director
Department of Gastrointestinal Surgery, Helsinki University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials